Bellicum pharmaceuticals, inc. (BLCM)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Cash flows from operating activities:
Net income (loss)

17,576

-28,981

-32,032

-26,936

-24,528

-27,220

-23,801

-24,175

-22,840

-21,918

-23,431

-24,457

-21,973

-19,938

-17,719

-16,509

-15,075

-16,848

-13,408

-10,534

-7,758

-74,298

-4,096

-3,281

-2,290

Adjustments to reconcile net loss to net cash used in operating activities:
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation

1,323

1,576

1,630

1,996

2,136

2,970

3,676

3,573

3,605

3,352

3,663

3,190

3,364

3,094

3,060

3,118

3,065

2,471

2,302

2,147

1,489

665

89

81

76

Depreciation and amortization expense

537

-

-

-

1,787

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of warrant and private placement option liabilities

-32,826

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization expense

-

-

-

-

-

-

-

1,774

1,426

1,040

876

866

782

687

668

488

463

430

394

179

196

182

164

162

159

Amortization of discount on investment securities, net

0

1

1

10

18

24

9

-36

-91

-88

-91

-62

-61

-90

-109

-156

-184

-196

-208

-169

0

-

-

-

-

Amortization of right-of-use assets

85

335

360

324

312

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion of lease liability

442

-214

-235

-222

-133

78

71

69

58

31

26

22

23

19

15

42

43

-

-

-

-

-

-

20

28

Amortization of lease liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-17

-

-

-

-

Amortization of deferred issuance costs

214

223

223

221

218

223

221

223

219

170

224

216

164

147

125

122

28

0

0

0

0

-

-

-

-

Changes in operating assets and liabilities:
Changes in operating assets and liabilities:
Accounts receivable, interest and other receivables

-257

-25

-209

-410

38

371

194

-77

101

-148

193

-9

-50

29

-77

21

-79

52

-74

368

-204

-923

-543

491

527

Prepaid expenses and other assets

435

-428

-812

1,014

1,322

-908

-291

200

-71

245

-502

167

1,020

-403

-226

-151

-105

386

-264

1,036

-91

1,300

62

-277

-17

Accounts payable

-849

1,343

-739

17

-1,752

1,904

361

-534

-1,271

411

664

-394

-1,193

1,419

638

-794

-332

572

720

-301

-94

-483

1,154

94

-106

Accrued liabilities and other

-1,695

-5,027

980

2,715

-968

-193

1,387

663

340

-1,621

92

526

-2,664

-380

1,429

-2

289

1,268

2,023

623

-1,136

715

134

-43

-581

Deferred revenue

0

-973

-103

-1,391

-516

-312

-292

-362

-154

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Deferred manufacturing costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-68

-47

229

62

Other liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Net cash used in operating activities

-16,255

-12,734

-18,788

-21,491

-24,556

-20,401

-16,680

-19,029

-18,672

-12,823

-17,538

-20,171

-22,452

-14,489

-11,402

-13,313

-11,237

-12,136

-7,439

-9,126

-7,025

-50,150

-948

-2,992

-3,218

Cash flows from investing activities:
Purchases of investment securities

-

-

-

-

-

-

18,184

26,145

6,312

18,612

8,263

16,533

11,487

7,160

3,416

1,685

21,015

22,549

5,481

73,619

0

-

-

-

-

Cash flows from investing activities:
Proceeds from sale of investment securities

0

4,150

9,550

17,516

18,163

19,123

14,429

20,535

17,275

18,201

6,516

17,595

21,425

16,781

9,909

4,675

11,183

12,874

5,416

2,327

0

-

-

-

-

Purchases of property and equipment

37

-32

3

420

131

296

266

639

416

1,580

2,981

5,980

1,593

1,433

1,220

2,274

2,293

824

1,851

1,813

933

403

279

100

22

Net cash (used in) provided by investing activities

-37

4,182

9,547

17,096

18,032

10,133

-4,021

-6,249

10,547

-1,952

-4,728

-4,918

8,345

8,188

5,273

716

-12,125

-10,499

-1,916

-73,105

-933

-403

-279

-100

-22

Cash flows from financing activities:
Payment on debt

2,000

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock in a public offering, net

0

0

0

4,352

4,625

195

0

64,665

0

-

0

-292

64,860

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of stock options

0

0

0

6

70

304

11

2,157

828

33

156

712

585

211

277

172

113

482

-82

80

2

-212

212

0

0

Proceeds from notes payable

-

-

-

-

-

-

-

-

-

-

0

0

10,000

-

5,000

0

15,000

-

-

-

-

-

-

-

-

Payments of Debt Issuance Costs

-

-

-

-

-

-

-

-

-

75

0

0

75

0

0

0

199

0

0

0

0

-

-

-

-

Payment on financing lease obligations

17

17

16

6

8

8

8

8

7

7

6

6

4

5

3

4

3

-1

5

0

0

-

-

-

-

Proceeds from issuance of Series B preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

7,320

Payment of issuance costs on common stock

-

-

-

-

-

-

-

-

-

-

-

-

28

-

-

-

0

-1

0

0

8

10,718

3,524

0

0

Proceeds from exercise of common warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

201

Proceeds from line of credit or notes payable or debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Payments on line of credit

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

100

100

100

Net cash (used in) provided by financing activities

-2,017

-199

65,177

4,423

4,687

372

3

66,913

821

2,389

150

609

75,338

387

5,274

356

14,911

389

196

239

-6

180,222

51,003

-100

7,421

Effect of exchange rate changes on cash

-13

-187

-23

-46

28

-98

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net change in cash, cash equivalents, and restricted cash

-18,322

-8,938

55,913

-18

-1,809

-9,994

-20,698

41,635

-7,304

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH

-

-

-

-

-

-

-

-

-

-

-

-

61,231

-5,914

-855

-12,241

-8,451

-

-

-

-

-

-

-

-

NET CHANGE IN CASH AND CASH EQUIVALENTS

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-9,159

-81,992

-7,964

-

49,776

-3,192

4,181

Supplemental cash flow information:
Cash paid during the period for interest

792

590

889

865

857

574

1,115

552

784

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest paid

-

-

-

-

-

-

-

-

-

-

-

743

488

-

-

-

-

0

0

0

0

-

-

-

-

Non-cash investing and financing activities:
Non-cash investing and financing activities:
Purchases of property and equipment in accounts payables and accrued liabilities

0

0

0

-5

5

-28

33

-197

219

-823

-1,311

-710

3,716

2,467

-53

559

560

139

0

0

0

-

-

-

-

Conversion of redeemable preferred stock into common stock

160

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Reclassification of property and equipment, net to assets held for sale

199

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued debt issuance costs

-

-

-

-

-

-

-

-

-

2,350

0

0

695

0

174

0

1,216

0

0

0

0

-

-

-

-

Accrued issuance costs for public offering

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

Capital lease obligations incurred for equipment

-

-

-

-

-

-

-

-

-

0

0

-228

251

12

0

15

19

70

65

0

0

-

-

-

-

Preferred stock dividends paid in common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,764

328

564

540